Journal article · 2021 · Open access

893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation

Hui Yuwen, Tengteng Li, Yijing Ren, Dirk Hoenemann, Jay M. Mei, Bo Shan, Bing Hou

Journal for ImmunoTherapy of Cancer, A936–A937 · Published 1 November 2021 · DOI 10.1136/jitc-2021-sitc2021.893

Open PDFView at the publisherCite this paper

In brief

“893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation” is a 2021 journal article by Hui Yuwen and 6 co-authors, published in Journal for ImmunoTherapy of Cancer. OpenAlex counts 4 citations as of 18 November 2026, which puts it in the top 7% of works published in 2021 by citations. It is open access: the full text is free to read at Journal for ImmunoTherapy of Cancer.

Citations
4
Most cited in
2023 (2)
Field-weighted impact
2.04
Authors
7

Abstract

Background Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1(PD-1) blockade therapy has revolutionized the treatment landscape of malignancies. However, only a minority of patients are anticipated to experience a deep and durable response. In addition, successful therapeutic agonism of 4-1BB, a promising co-stimulatory immunologic target, has been limited by major safety concerns of hepatotoxicity or suboptimal agonistic potency. ATG-101, a novel PD-L1/4-1BB bispecific antibody, was designed to activate 4-1BB positive T cells in a PDL1-crosslinking dependent manner and to effectively treat tumors without on-target-off-tumor liver toxicity (figure 1). Methods ATG-101 was developed by introducing lower affinity 4-1BB scFv into a human IgG1 PD-L1 monoclonal antibody. The N297A mutation on CH2 abolishes the binding capacity to most FcγRs but retains the binding to FcγRn. A series of in vitro and in vivo studies were performed to evaluate the potency, safety and specific mechanism of action. Results ATG-101 simultaneous binds to 4-1BB and PD-L1 with higher affinity to PD-L1, and potently activates 4-1BB positive T cells when crosslinked by PD-L1 positive cells. Upon crosslinking, ATG-101 also activates PD1+TIM3+ exhausted T cells in vitro, suggesting a potential in reversing T-cell dysfunction and exhaustion (figure 1). ATG-101 shows potent anti-tumor activities in various animal models, including h4-1BB humanized mice bearing MC38 colon cancer, PD(L)1 blockade insensitive B16F10 melanoma and EL4 lymphoma, with no body weight loss observed. To evaluate ATG-101 efficacy in tumors progressing after anti-PD(L)1 treatment, mice bearing MC38 tumors were treated with anti-PDL1 initially to achieve tumor growth inhibition, and half of the mice switched to ATG-101 upon disease progression, the other mice continuing with anti-PD-L1 treatment. ATG-101 induced potent tumor growth inhibition and tumor regression in anti-PDL1-resistant tumors and prolonged survival. Flow cytometry and multiplex IHC staining of tumor samples from mice treated with ATG-101 or control suggest that ATG-101 increases the infiltration, proliferation and activation of CD8+ T cells (figure 2), the infiltration of natural killer T cells and the CD8+/Treg ratio in TILs. In a 4-week GLP toxicity study in cynomolgus monkey, up to 100mg/kg repeated doses of ATG-101 were well tolerated with no hepatotoxicity observed. Conclusions ATG-101 demonstrated significant anti-tumor activity in various tumor models including those progressing on anti PD(L)1 treatment. Good safety and PK/PD properties has been demonstrated in preclinical in vivo models. A phase I, multicenter, dose-escalating clinical trial evaluating ATG-101 in patients with solid tumors and hematologic malignancies is ongoing. Ethics Approval The protocol and any amendment(s) or procedures involving the care and use of animals in this study were reviewed and…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Yuwen, H., Li, T., Ren, Y., Hoenemann, D., Mei, J. M., Shan, B., & Hou, B. (2021). 893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation. Journal for ImmunoTherapy of Cancer, A936–A937. https://doi.org/10.1136/jitc-2021-sitc2021.893

MLA 9

Yuwen, Hui, et al. “893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation.” Journal for ImmunoTherapy of Cancer, 2021, pp. A936–A937. https://doi.org/10.1136/jitc-2021-sitc2021.893.

Chicago

Yuwen, Hui, Tengteng Li, Yijing Ren, Dirk Hoenemann, Jay M. Mei, Bo Shan, and Bing Hou. 2021. “893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation.” Journal for ImmunoTherapy of Cancer: A936–A937. https://doi.org/10.1136/jitc-2021-sitc2021.893.

Harvard

Yuwen, H. et al. (2021) ‘893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation’, Journal for ImmunoTherapy of Cancer, pp. A936–A937. doi:10.1136/jitc-2021-sitc2021.893.

IEEE

H. Yuwen et al., “893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation,” Journal for ImmunoTherapy of Cancer, pp. A936–A937, 2021, doi: 10.1136/jitc-2021-sitc2021.893.

BibTeX

@article{yuwen2021novel,
  title     = {{893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation}},
  author    = {Yuwen, Hui and Li, Tengteng and Ren, Yijing and Hoenemann, Dirk and Mei, Jay M. and Shan, Bo and Hou, Bing},
  journal   = {Journal for ImmunoTherapy of Cancer},
  year      = {2021},
  pages     = {A936--A937},
  doi       = {10.1136/jitc-2021-sitc2021.893},
  url       = {https://doi.org/10.1136/jitc-2021-sitc2021.893}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • PD-L1 blockade
  • immune checkpoint blockade
  • T cell exhaustion
  • anti-PD-L1 resistance
  • anti-PD-1 resistance
  • hepatotoxicity
  • antitumor immunity
  • colon cancer

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Yuwen, H., Li, T., Ren, Y., Hoenemann, D., Mei, J. M., Shan, B., & Hou, B. (2021). 893 ATG-101, a novel PD-L1/4–1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4–1BB activation. Journal for ImmunoTherapy of Cancer, A936–A937. https://doi.org/10.1136/jitc-2021-sitc2021.893

How many times has this paper been cited?

4 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal for ImmunoTherapy of Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Hui Yuwen, Tengteng Li, Yijing Ren, Dirk Hoenemann, Jay M. Mei, Bo Shan, Bing Hou.

What is the DOI of this paper?

10.1136/jitc-2021-sitc2021.893, permanently at https://doi.org/10.1136/jitc-2021-sitc2021.893. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.